CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

The article explores C-Reactive Protein (CRP) as a promising biomarker for assessing immune responses in cancer patients. It highlights the advantages of Low-Reactive Protein (LRP), a high-sensitivity test for CRP, which provides more accurate measurements of inflammation. The authors present findings from serial L-CRP measurements across various advanced cancer cases, revealing cyclical variations in CRP levels that suggest a homeostatic immune response. They propose that understanding these oscillations could enhance treatment timing and efficacy. The article advocates for further investigation into CRP's role in immune regulation and its potential as a tool for optimizing cancer therapies.